REDEFINE-1 Body Composition Data: How CagriSema Affects Muscle Mass

What was presented

REDEFINE-1 enrolled 3,417 adults with obesity (or with overweight plus at least one related comorbidity) and randomized them in a 21:3:3:7 ratio to once-weekly subcutaneous CagriSema 2.4/2.4 mg, semaglutide 2.4 mg alone, cagrilintide 2.4 mg alone, or placebo — all on top of a reduced-calorie diet and physical activity. The 68-week primary readout was published last year and showed CagriSema producing roughly 20% mean weight loss, with more than 91% of participants hitting at least 5% body-weight reduction.

The ECO 2026 presentation looked at a different question. Investigators ran sit-to-stand testing in 1,038 participants and DXA scans on 252 of them to separate fat mass from lean soft tissue, and they checked whether body-composition changes correlated with physical-function changes. The full sub-analysis was framed as an evaluation of muscle strength, body composition, and how the two relate — important context given a recognized concern that modern obesity pharmacotherapy may reduce lean mass alongside fat.

Why this matters for peptide research

The lean-mass question has shadowed every high-efficacy GLP-1 from the start. When the absolute weight-loss number is 20% or higher, the composition of what's lost becomes clinically meaningful: fat mass loss is the goal, but lean mass loss in older patients raises sarcopenia and physical-function concerns. The honest answer in the literature so far has been that some lean-mass loss occurs with GLP-1 monotherapy, that it's roughly proportional to overall weight loss, and that it's mitigated — but not eliminated — by resistance training during treatment.

CagriSema's specific question is whether adding an amylin analogue to a GLP-1 changes that picture. Cagrilintide acts at the calcitonin and amylin receptors and has a different mechanism than the incretin-class drugs (semaglutide, tirzepatide, retatrutide) that dominate the current pipeline. If the body-composition picture under combined GLP-1 + amylin therapy differs meaningfully from GLP-1 alone, that has implications for how future peptide stacks get designed.

What we don't know yet

This was a post-hoc analysis on a sub-sample, not a powered comparison. Full numbers — percent of weight loss attributable to fat versus lean tissue, strength-test deltas by arm — will need peer-reviewed publication. The DXA cohort of 252 is small relative to the trial's size, and sit-to-stand testing is useful but coarse.

CagriSema's FDA decision is still expected by late 2026. REDEFINE 11, which will test higher doses, is expected to read out in the first half of 2027.

Related on Grey Peptides